4 results on '"Agnese G."'
Search Results
2. Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19
- Author
-
Viceconte G., Buonomo A. R., Lanzardo A., Pinchera B., Zappulo E., Scotto R., Schiano Moriello N., Vargas M., Iacovazzo C., Servillo G., Gentile I., Francesco B., Letizia C., Carmela Domenica C. M., Mariarosaria C., Giovanni D. F., Maria F., Antonella G., Ivan G., Agnese G., Simona M., Fulvio M., Amerigo P., Laura R., Fabrizio S., Alessia S., Francesca S., Grazia T., Irene Z., Viceconte, G., Buonomo, A. R., Lanzardo, A., Pinchera, B., Zappulo, E., Scotto, R., Schiano Moriello, N., Vargas, M., Iacovazzo, C., Servillo, G., Gentile, I., Francesco, B., Letizia, C., Carmela Domenica, C. M., Mariarosaria, C., Giovanni, D. F., Maria, F., Antonella, G., Ivan, G., Agnese, G., Simona, M., Fulvio, M., Amerigo, P., Laura, R., Fabrizio, S., Alessia, S., Francesca, S., Grazia, T., and Irene, Z.
- Subjects
0301 basic medicine ,Microbiology (medical) ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,030106 microbiology ,03 medical and health sciences ,0302 clinical medicine ,parasitic diseases ,Medicine ,Pneumocystis jirovecii ,In patient ,030212 general & internal medicine ,Aspergillus ,General Immunology and Microbiology ,biology ,business.industry ,SARS-CoV-2 ,Pneumocystis jirovecii Pneumonia ,COVID-19 ,General Medicine ,biology.organism_classification ,Virology ,invasive fungal disease ,Infectious Diseases ,Pneumocystis carinii ,lymphopaenia ,Immunocompetence ,business - Abstract
Background: Several cases of invasive fungal diseases in patients with COVID-19 have been reported, mostly due to Aspergillus spp., with anecdotic reports of Pneumocystis jirovecii pneumonia (PJP) as co-infections in immunocompromised patients. We describe the first case of PJP in an immunocompetent patient who recovered from COVID-19 pneumonia. Case description: Our patient was hospitalized for 18 d for respiratory failure due to Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pneumonia and successfully treated with continuous positive airway pressure (CPAP) respiratory support, enoxaparin, ceftaroline and intravenous 6 mg of dexamethasone for 10 d, then with oral prednisone tapering. Despite his improved radiological and clinical conditions at discharge, he was admitted again after 18 d for worsening of respiratory conditions. Upon the second admission, a high-resolution CT-scan of the chest showed the development of new ground-glass opacities and P. jirovecii was detected on bronchoalveolar lavage fluid. A therapy with trimethoprim-sulphamethoxazole 20 mg/kg and methylprednisolone 40 mg i.v. bis in die (BID) was started, with improvement of clinical, biochemical and radiological conditions. Conclusions: COVID-19 patients may have multiple risk factors for development of PJP, in particular lymphopaenia and use of steroids. PJP must be ruled out with direct microbiological methods in patients presenting with radiologic and clinical features of possible or probable PJP, even in immunocompetent hosts.
- Published
- 2021
3. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019.
- Author
-
Riccardo BA, Gabriele S, Nunzia E, Isabella DF, Biagio P, Maria F, Emanuela Z, Agnese G, Nicola SM, Giulio V, Riccardo S, Giuseppe B, and Ivan G
- Subjects
- Humans, Female, Pregnancy, Adult, Prospective Studies, COVID-19, Antiviral Agents therapeutic use, Antiviral Agents administration & dosage, Hospitalization, Drug Combinations, Oxygen Inhalation Therapy, Antibodies, Neutralizing, Pregnancy Complications, Infectious drug therapy, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, COVID-19 Drug Treatment, SARS-CoV-2
- Abstract
Objective: Our objective was to evaluate the safety and efficacy of casirivimab/imdevimab therapy in pregnant women with severe coronavirus disease 2019 (COVID-19) requiring oxygen therapy., Study Design: This was a prospective case series study aimed to evaluate the safety and efficacy of casirivimab/imdevimab therapy in unvaccinated pregnant women with severe COVID-19. Inclusion criteria were severe acute respiratory syndrome coronavirus 2 infection documented with polymerase chain reaction, pregnancy, severe COVID-19 requiring oxygen therapy, duration of symptoms of 10 days or less, and able to provide informed consent. Vaccinated women and those with mild-to-moderate disease were excluded from the study. Included patients received casirivimab and imdevimab as a single intravenous dose of 4,000/4,000 mg. Women were also treated with low molecular weight heparin, steroids, and antibiotics, if necessary. The primary outcome was maternal death. Secondary outcomes were the rate of adverse events during infusion or within 72 hours and the rate of abortion., Results: Thirteen hospitalized unvaccinated pregnant women with severe COVID-19 requiring oxygen and treated with casirivimab/imdevimab were included in the study. We observed no maternal death, and no patients required intubation or admission to the intensive care unit. No abortion or fetal loss was recorded. Nine pregnancies were still ongoing, and there were three cesarean deliveries and one vaginal delivery. Two were preterm deliveries (at 31 and 34 weeks), and two were term deliveries., Conclusion: Casirivimab/imdevimab therapy may be considered as a therapy in unvaccinated pregnant women with severe COVID-19., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Human papilomaviru-related oropharyngeal squamous cell carcinoma and radiomics: A new era?
- Author
-
Caprini E, D'Agnese G, Brennan PA, and Rahimi S
- Subjects
- Humans, Squamous Cell Carcinoma of Head and Neck, Artificial Intelligence, Neoplasm Recurrence, Local diagnostic imaging, Human Papillomavirus Viruses, Cyclin-Dependent Kinase Inhibitor p16 analysis, Papillomaviridae, Head and Neck Neoplasms, Oropharyngeal Neoplasms pathology, Carcinoma, Squamous Cell pathology, Papillomavirus Infections complications, Papillomavirus Infections diagnostic imaging
- Abstract
Background: The increase of the incidence of human papillomavirus dependent oropharyngeal squamous cell carcinoma is alarming, although we have greatly progressed in the classification and staging of this disease. We now know that human papillomavirus related oropharyngeal squamous cell carcinoma is a sub-type of head and neck squamous cell carcinoma with favourable prognosis and good response to therapy that needs a proper system of classification and staging. Thus, in routine practice it is essential to test patients for the presence of human papillomavirus. The most popular technique to assess human papillomavirus status is immunohistochemistry on biopsy samples with p16, which is an excellent surrogate for high-risk human papillomavirus infection. Another highly sensitive and specific tissue-based technique for the detection of human papillomavirus is RNAscope In situ hybridization that has a prohibitive cost, limiting its use in routine practice. Radiomics is an artificial intelligence based non-invasive method of computational analysis of computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound images., Methods: In this review, we summarise the last findings of radiomics applied to human papillomavirus associated oropharyngeal squamous cell carcinoma., Results: A growing body of evidence suggest that radiomics is able to characterise and detect early relapse after treatment, and enable development of tailored therapy of human papillomavirus positive oropharyngeal squamous cell carcinoma., (© 2023 The Authors. Journal of Oral Pathology & Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.